<?xml version="1.0" encoding="UTF-8" standalone="no"?><information><Cell><NavigationPath><Head00>No. of cycles Grade</Head00><Stub><SubHeader0>Neurological</SubHeader0><StubValue> Motor</StubValue></Stub><HeaderValue>Carboplatin 379 4</HeaderValue></NavigationPath><value>0</value><CellType>Numeric</CellType></Cell><Table><tableName>Percentage of cycles of chemotherapy complicated by toxicity</tableName><TableType>Subheader</TableType><tableOrder>Table 3</tableOrder><tableFooter/></Table><Document><DocumentTitle>SCOTROC 2B: feasibility of carboplatin followed by docetaxel or docetaxel–irinotecan as first-line therapy for ovarian cancer</DocumentTitle><PMC>2361090</PMC></Document></information>